Skip to content
An Initiative of AVAC
Search
Back to Resource Library

South Africa Lenacapavir Implementation Guidelines, 2025

8 December 2025

This guideline, developed by South Africa’s National Department of Health, is intended to provide comprehensive clinical, programmatic, and operational direction for the safe, effective, and equitable rollout of lenacapavir as a long-acting injectable option for HIV PrEP in South Africa.

Topic(s): Normative Guidance/Policies

Product(s): Injectable Prep, Lenacapavir

Region(s): Sub-Saharan Africa

Format(s): Report

Countries: South Africa

Source(s): South Africa National Department of Health

Type: Document

Download

Featured Resources

Document

Ukraine HIV Clinical Guidelines 2025

These clinical guidelines, released by the Ukraine Ministry of Health in 2025, include the latest recommendations for HIV services, including oral PrEP and injectable cabotegravir (CAB) for PrEP.
External Link

BLUPrInt PrEP Program Builder

The BLUPrInt PrEP Program Builder breaks down the process of making PrEP – whether oral or injectable – available in your setting into six manageable and coherent program components. Each program component includes a Step-by-Step Guide that presents key decision points and health equity considerations that are crucial to PrEP program development, a templated Standard…
Spreadsheet

Site/Facility Readiness Assessment Tool to Support Lenacapavir for HIV Prevention Introduction

This tool, developed by Wits RHI and CHAI with support from Unitaid, is intended to provide insight into the current state of PrEP services and to identify critical barriers and facilitators to PrEP implementation with a focus on preparing for Lenacapavir (LEN) introduction according to national requirements. Findings from readiness assessment visits using this tool…
Document

Getting LEN Rollout Right: Resources and Tools

The resources listed in this document, alongside insights drawn from the report Getting PrEP Rollout Right This Time, can support countries in the early stages of LEN planning. These tools are being disseminated as part of a coordinated effort between AVAC, CHAI, the Global Fund, PEPFAR, Unitaid, Wits RHI, and WHO under the Coalition to…
Document

Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda, 2022

These guidelines, produced in 2022 by the Uganda Ministry of Health, provide guidance on the diagnosis of HIV, the care of people living with HIV, and the use of antiretroviral drugs for treating and preventing HIV infection, including injectable cabotegravir and the dapivirine vaginal ring.
Document

Malawi Service Delivery Guidelines and Standard Operating Procedures for the Provision of HIV Pre-Exposure Prophylaxis using Oral or Long-acting Injectable Options (2024)

The document, produced by the Malawi Ministry of Health, is a guideline to support funders, implementing partners, district health team leads and service providers in implementing Oral and Long-Acting Injectable PrEP in Malawi.
External Link

Preferences for Long-acting Injectable HIV Pre-exposure Prophylaxis Service Delivery among Male and Female Sex Workers in Uganda: A discrete choice experiment

This article from PLOS Global Public Health explores service delivery preferences for injectable cabotegravir among heterosexual male sex workers and female sex workers in Uganda.
Document

Lenacapavir Provider Tools and Job Aids

These editable tools, developed by Wits RHI, can be used to support providers delivering lenacapavir (LEN) for PrEP. The downloadable zip file includes: LEN Factsheet for Clients LEN Counselling Job Aid for Clinicians LEN Counselling Job Aid for Counsellors LEN Initiation Algorithm LEN Injection Procedure Chart HIV Prevention Product Comparison Table LEN Stopping and Switching…
Presentation

Prevention with PURPOSE

This presentation, delivered by Dr Linda-Gail Bekker at IAS 2025, provides an overview of PURPOSE 1 and 2 lenacapavir clinical trial results as well as special considerations for administration to different populations and drug-drug interactions.
External Link

Dynamic Choice HIV Prevention with Long-acting Injectable Cabotegravir Pre-exposure Prophylaxis in East, Central, Southern, and West Africa: A cost-effectiveness modelling analysis

In randomised controlled trials in Kenya and Uganda, a dynamic choice HIV prevention intervention that offered structured choice of biomedical prevention product and opportunity to change products over time substantially improved prevention coverage; incident HIV infections were eliminated when long-acting cabotegravir was included as an option. This article from The Lancet HIV aims to assess…